Evidence-Based Medicine Guidelines
Natalizumab for relapsing remitting multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Natalizumab for Relapsing Remitting Multiple Sclerosis." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/457426/all/Natalizumab_for_relapsing_remitting_multiple_sclerosis.
Natalizumab for relapsing remitting multiple sclerosis. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/457426/all/Natalizumab_for_relapsing_remitting_multiple_sclerosis. Accessed December 18, 2024.
Natalizumab for relapsing remitting multiple sclerosis. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/457426/all/Natalizumab_for_relapsing_remitting_multiple_sclerosis
Natalizumab for Relapsing Remitting Multiple Sclerosis [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 December 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/457426/all/Natalizumab_for_relapsing_remitting_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Natalizumab for relapsing remitting multiple sclerosis
ID - 457426
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/457426/all/Natalizumab_for_relapsing_remitting_multiple_sclerosis
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
